BioMarin to Acquire Amicus, Expanding Rare Disease Portfolio

BioMarin Pharmaceutical ( (BMRN) ) has shared an update.

On December 19, 2025, BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics in an all-cash deal valuing Amicus at approximately $4.8 billion, or $14.50 per share, a premium of up to 58% over recent trading averages. The transaction, unanimously approved by both boards and recommended by Amicus’ directors, is expected to close in the second quarter of 2026, subject to shareholder approval and antitrust clearances, and will be financed through a mix of cash and about $3.7 billion in new non-convertible debt backed by a bridge facility from Morgan Stanley. The acquisition will add Amicus’ marketed rare disease drugs Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, as well as U.S. rights to late-stage kidney disease candidate DMX-200, immediately expanding and diversifying BioMarin’s rare disease portfolio and revenue base. BioMarin forecasts that the deal will accelerate long-term revenue growth, be accretive to non-GAAP earnings per share within 12 months of closing and substantially accretive from 2027, while targeting gross leverage below 2.5x within two years. In a related move that strengthens the combined company’s intellectual property position, Amicus also resolved U.S. patent litigation over Galafold, granting generic rivals licenses that allow entry no earlier than January 30, 2037, thereby extending expected U.S. market exclusivity for the drug and underpinning its projected contribution to BioMarin’s growth and cash flow profile.

The most recent analyst rating on (BMRN) stock is a Hold with a $60.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.

Spark’s Take on BMRN Stock

According to Spark, TipRanks’ AI Analyst, BMRN is a Outperform.

BioMarin Pharmaceutical’s strong financial performance and positive earnings call sentiment are the most significant factors contributing to its score. The company’s robust revenue growth and solid cash position are key strengths. Technical analysis and valuation present a mixed picture, with moderate bullish momentum and fair valuation. The absence of corporate events and dividend yield are typical for the industry.

To see Spark’s full report on BMRN stock, click here.

More about BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for rare diseases, particularly lysosomal storage disorders. Its portfolio includes enzyme replacement and other specialized treatments marketed globally, supported by in-house manufacturing capabilities and an established international commercial footprint.

Average Trading Volume: 2,618,921

Technical Sentiment Signal: Sell

Current Market Cap: $9.95B

See more data about BMRN stock on TipRanks’ Stock Analysis page.